(Q36802632)

16 August 2017

1 reference

title

Review of dalbavancin, a novel semisynthetic lipoglycopeptide (English)

1 reference

16 August 2017

3

David P Nicolau

1 reference

16 August 2017

Aryun Kim

1

1 reference

16 August 2017

Joseph L Kuti

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

16

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

717-733

1 reference

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

The impact of antimicrobial resistance on health and economic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Trends in antimicrobial drug development: implications for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Origin, structure, and activity in vitro and in vivo of dalbavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Glycopeptide antibiotics: from conventional molecules to new derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

21 January 2018

Glycopeptide derivatives

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Glycopeptide and lipoglycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Glycopeptides: Update on an old successful antibiotic class

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Antipneumococcal activity of dalbavancin compared to other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Pharmacokinetics and excretion of dalbavancin in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Effect of dalbavancin on the normal intestinal microflora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.717

10.1517/13543784.16.5.717

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference